News Feed
OncoDaily Pulse
OncoGrants
OncoDaily TV
NewsLetter
Voices
FDA Approvals
New Paper Alert
Community
Career Updates
Oncology Drugs
Dialogues
Stories

Celebrities and Cancer
Cancer Types
Radiotherapy
Science
Trial Updates
ASCO
ESMO
ESO
MASCC
Cancer Center Near Me
Immune Oncology
Oncologist Near Me
OncoDaily Party 2025

Childhood Cancer
Health Policy
Hall of Fame
Industry
Public Health
Techology
Blog Posts
BIGR
Global Cancer Movement
History
Oncolibrary
Oncothon 2025
Yvonne Award 2025

Sep / 2025

September 2025
M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

« Aug

OncoDaily IO OncoDaily GI Hemostasis Today

Voices
FDA Approvals
New Paper Alert
Community
Career Updates
Oncology Drugs
Dialogues
Stories

News Feed
OncoDaily Pulse
OncoGrants
OncoDaily TV
NewsLetter

Toni Choueiri

Toni Choueiri

Toni Choueiri

Toni Choueiri

Toni Choueiri

Toni Choueiri

Toni Choueiri

Toni Choueiri

Thomas Powles

Jul 14, 2024 5:55 am

Blog Posts

RNA vaccines generate tumour specific immune responses with limited toxicity

Toni Choueiri

Jun 28, 2024 2:34 pm

Blog Posts

María Natalia Gandur Quiroga: Imfinzi Shows Significant Survival Benefits in NIAGARA Phase III Trial

María Natalia Gandur Quiroga

Jun 26, 2024 8:30 am

Insight

IMFINZI (durvalumab) showed improved EFS and OS for MIBC in NIAGARA Phase III trial

AstraZeneca

Apr 20, 2024 6:03 am

Insight

Toni Choueiri: The long-awaited OS results from KEYNOTE-564 are out at the New England Journal of Medicine!

Toni Choueiri

Feb 1, 2024 3:42 pm

Opinion

Thomas Powles: Enfortumab Vedotin and Pembrolizumab shows broad spectrum of activity for Regional Recurrence, Progression-free survival and Overall Survival in all subgroups

Thomas Powles: Enfortumab Vedotin and Pembrolizumab shows broad spectrum of activity for Regional Recurrence, Progression-free survival and Overall Survival in all subgroups

Jan 31, 2024 3:42 pm

Blog Posts

Thomas Powles: We need better biomarkers in Urothelial Carcinoma

Thomas Powles: We need better biomarkers in Urothelial Carcinoma

4

Headlines

W. Michael Korn: Biocartis Received FDA Approval for the Idylla CDx MSI Test

The 2025 China-Hungary Anti-Cancer Summit: Bridging Expertise in Cancer Care

The Servier Golden Ticket is Back in 2025!

Eduardo Bruera: Palliative Care Education and Research at US Cancer Centers

Richard Sullivan: Global Health Funding Is Vaporising, Cancer Research Under Threat

CancerWorld OncoDaily Medical Journal Hemostasis Today OncoDaily IO OncoDaily GI OncoDailyTV

OncoDaily™ | © 2023 - 2025

All rights reserved. Unauthorized reproduction, distribution, or transmission of any content on OncoDaily.com is strictly prohibited. For permission requests or inquiries, please contact OncoDaily directly. By accessing and using OncoDaily.com, you acknowledge and agree to comply with this copyright notice, as well as our Privacy Policy, Editorial Policy, Cookie Policy, and Disclaimer. Continued use of this website constitutes acceptance of all such terms and policies.

Phone number: +1 978 717 48 84

Email: [email protected]

About Privacy Policy Editorial Policy Cookie Policy Disclaimer

Crafted by Matemat

OncoDaily

Oncology

cancer

fight against cancer

Global fight against cancer

cancer care

Breast Cancer

ASCO

Lung cancer

Cancer research

MD Anderson Cancer Center

cancer awareness

NSCLC

ESMO

immunotherapy

cancer treatment

Research

ASCO24

Headlines

colorectal cancer

Childhood Cancer

prostate cancer

AACR

clinical trials

FDA

Dana-Farber Cancer Institute

UICC

American Cancer Society

European Cancer Organisation

NCI

National Cancer Institute

healthcare

SIOP

ASCO25

chemotherapy

Vivek Subbiah

AI

American Society of Clinical Oncology

Paolo Tarantino

IASLC

WHO

Robert Orlowski

multiple myeloma

Memorial Sloan Kettering Cancer Center

Zainab Shinkafi-Bagudu

radiation oncology

Myeloma Paper of the Day

cervical cancer

Myeloma

patient care

European School of Oncology

Sitemap

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage {vendor_count} vendors Read more about these purposes

View preferences

{title} {title} {title}

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage {vendor_count} vendors Read more about these purposes

View preferences

{title} {title} {title}